Chemomab Therapeutics News

Chemomab Therapeutics | 20-F: Registration statement / Annual report / Transition report

Mar 28 06:14 ET

Chemomab Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Israel BioFund GP Limited Partnership(16.0%),OrbiMed Israel GP Ltd.(16.0%), etc.

Mar 11 19:23 ET

Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Mar 7 07:04 ET

Chemomab Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Jan 3 00:00 ET

Chemomab Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Israel BioFund GP Limited Partnership(18.3%),OrbiMed Israel GP Ltd.(18.3%), etc.

Nov 15, 2023 16:35 ET

Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Nov 9, 2023 08:00 ET

Chemomab Therapeutics | EFFECT: Others

Nov 6, 2023 00:15 ET

Chemomab Therapeutics | CORRESP: CORRESP

Nov 1, 2023 16:05 ET

Chemomab Therapeutics | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment)

Oct 30, 2023 08:33 ET

Chemomab Therapeutics | F-3: Registration statement for specified transactions by certain foreign private issuers

Oct 16, 2023 16:25 ET

Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Aug 14, 2023 08:05 ET

Chemomab Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Aug 8, 2023 06:00 ET

Chemomab Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Darvish Nissim

Jul 5, 2023 17:48 ET

Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

Jul 3, 2023 15:49 ET

Chemomab Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Quigley Jill M.

Jun 20, 2023 06:03 ET

Chemomab Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Fatal Sigal

Jun 16, 2023 16:03 ET

Chemomab Therapeutics | 8-K: Current report

Jun 16, 2023 16:01 ET

Chemomab Therapeutics | 3: Initial statement of beneficial ownership of securities-Chief Financial Officer Fatal Sigal

Jun 5, 2023 16:54 ET

Chemomab Therapeutics | 8-K: Current report

Jun 5, 2023 07:00 ET

Chemomab Therapeutics | RW: Registration Withdrawal Request

Jun 2, 2023 16:02 ET